Related Content
![Brightline-2 trial initiated in biliary tract and pancreatic cancers](/sites/default/files/us/2023-02/Brightline-2-biliary-tract.jpg)
Gastrointestinal Cancers
Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial
Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.
Read more